04 June, 2017
They now have a $5.00 price objective on the medical instruments supplier's stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. increased its stake in shares of Endologix by 17,682.9% in the first quarter. Renaissance Technologies LLC now owns 344,522 shares of the medical instruments supplier's stock valued at $1,971,000 after buying an additional 55,800 shares during the last quarter. FIL Ltd now owns 882,214 shares of the medical instruments supplier's stock valued at $5,046,000 after buying an additional 3,564 shares during the period. Brown Capital Management LLC increased its position in shares of Endologix by 43.7% in the first quarter. Arrowpoint Asset Management LLC now owns 6,491,647 shares of the medical instruments supplier's stock worth $37,132,000 after buying an additional 1,035,975 shares during the period. Two Sigma Investments LP acquired a new stake in shares of Endologix during the fourth quarter worth $547,000.
11/16/2016 - Endologix, Inc. was downgraded to "neutral" by analysts at JP Morgan. Shares closed down 36.70% yesterday and hit as low as $4.20. The company has a 50 day moving average price of $6.89 and a 200-day moving average price of $7.01. The stock's market capitalization is 564.23M, it has a 52-week low of 4.78 and a 52-week high of 14.49.
11/16/2016 - Endologix, Inc. was downgraded to "market perform" by analysts at BMO Capital Markets.
Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Thursday, May 4th.
Endologix, Inc. (NASDAQ:ELGX) yearly performance is -42.72% and net profit margin is -66.40%.
The Company will collaborate with the FDA over the coming months on the confirmatory clinical study protocol and anticipates beginning patient enrollment in the fourth quarter of this year with PMA approval estimated to occur in 2020. During the same period in the prior year, the business earned ($0.25) earnings per share.
The company reported an impressive total revenue of 192.93 Million in the last fiscal year. Analysts expect that Endologix, Inc. will post ($0.63) earnings per share for the current year. NY Has $332,000 Stake in Endologix, Inc.
TRADEMARK VIOLATION NOTICE: This report was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was stolen and republished in violation of United States & worldwide trademark & copyright laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/05/19/endologix-inc-elgx-shares-bought-by-renaissance-technologies-llc-updated-updated-updated.html.
Several research analysts have recently issued reports on ELGX shares.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Endologix Inc. the EPS stands at -0.18 for the previous quarter, while the analysts predicted the EPS of the stock to be -0.21, suggesting the stock exceeded the analysts' expectations. Stephens downgraded Endologix from an "overweight" rating to an "equal weight" rating and set a $6.00 target price on the stock.in a research report on Thursday, May 18th. Royal Bank of Canada reaffirmed a "hold" rating on shares of Endologix in a research note on Thursday. Zacks Investment Research cut Endologix from a "buy" rating to a "hold" rating in a report on Wednesday, March 1st. Eleven analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company now has a consensus rating of "Hold" and an average target price of $8.43. Following the transaction, the director now directly owns 68,689 shares in the company, valued at approximately $304,292.27. The disclosure for this purchase can be found here. 1,337,190 shares of the company's stock were exchanged.
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally.
The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.
